Access to acute anemia agent under study may be expanded

August 27, 2007

Biopure Corp. has drafted a protocol for patients with life-threatening anemia for whom blood transfusion is not feasible to obtain its investigational product Hemopure (HBOC-201) on a compassionate-use basis.

Access to acute anemia agent under study may be expanded Biopure Corp. has drafted a protocol for patients with life-threatening anemia for whom blood transfusion is not feasible to obtain its investigational product Hemopure (HBOC-201) on a compassionate-use basis. The draft protocol lists the eligibility criteria for patients. The Cambridge, Mass., firm is awaiting word from the FDA to its draft protocol.